Study title: Gambertoglio JG, Lilleby K, Meyers JD, Reusser P. 1992.Phase i-ii trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. Journal of Infectious Diseases 1992;166(3):473-9 1992;(3):473-479.Gambertoglio JG, Lilleby K, Meyers JD, Reusser P. 1992.Phase i-ii trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. Journal of Infectious Diseases 1992;166(3):473-9 1992;(3):473-479.
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Virus Diseases [C02] | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: Foscarnet | |||||
| ATC code: | |||||
| Document link: Reusser et al 1992.pdf | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | Y | |